Robotic cardiac surgery represents an advanced evolution in cardiothoracic surgery. Instead of performing a median sternotomy (cutting through the breastbone), the surgeon operates through several quarter-inch incisions between the ribs using robotic surgical instruments. The primary goals of robotic cardiac surgery are to restore normal cardiovascular anatomical function—such as repairing leaky heart valves or bypassing blocked coronary arteries—while minimizing surgical trauma, blood loss, and recovery time. The procedure is performed under general anesthesia with cardiopulmonary bypass (heart-lung machine) support connected through blood vessels in the groin.

Robotic cardiac surgery is conducted under general anesthesia with double-lumen endotracheal intubation for single-lung ventilation. The surgical team establishes peripheral cardiopulmonary bypass by cannulating the femoral artery and vein through a small incision in the groin. Four to five small port incisions (8mm to 12mm) are made in the right intercostal spaces of the chest wall. The robotic camera and articulated surgical tools are inserted and docked to the robotic arms. The patient's heart is safely stopped using cardioplegia solution delivered through a specialized endoaortic balloon or transthoracic clamp. The surgeon sits at an ergonomic console using master controls to perform delicate intracardiac repairs, such as leaflet resection, artificial chordae placement, or annuloplasty ring attachment. Following repair validation, the heart is re-warmed, restarted, and cardiopulmonary bypass is weaning is completed. Port sites and groin incisions are closed in layers.

Clinical data from the Society of Thoracic Surgeons (STS) Database demonstrate several clear benefits of robotic cardiac surgery compared to open sternotomy:

• Reduced Surgical Trauma: Avoidance of sternum division eliminates bone healing constraints and lowers wound infection rates.
• Decreased Blood Loss: Significantly lower intraoperative and postoperative transfusion rates.
• Shorter Hospitalization: Average hospital length of stay is reduced from 7–9 days down to 3–5 days.
• Accelerated Recovery: Patients typically return to driving and work within 2 to 4 weeks, compared to 8 to 12 weeks after open surgery.
• Superior Visualization: 3D high-definition magnification improves precise leaflet repair rates in mitral valve surgery to over 95%.

Recovery following robotic cardiac surgery is divided into immediate, short-term, and long-term phases. Patients spend 12 to 24 hours in the cardiac ICU for close hemodynamic monitoring before transfer to a step-down telemetry unit. Chest drains and groin cannulas are typically removed within 24 to 48 hours. Most patients are discharged home on hospital day 3 or 4. Light walking is encouraged immediately upon discharge. Full physical activities, including driving and returning to non-manual work, are generally approved by 3 to 4 weeks post-surgery. Complete resolution of intercostal port site discomfort occurs within 4 to 6 weeks.

Robotic cardiac surgery is indicated for several structural and ischemic heart conditions, including:

• Mitral Valve Disease: Severe mitral regurgitation (leaky valve) or stenosis caused by degenerative leaflet prolapse, myxomatous valve disease, or chordal rupture.
• Coronary Artery Disease: Isolated or multivessel blockages suitable for totally endoscopic coronary artery bypass (TECAB), particularly involving the left anterior descending (LAD) artery.
• Atrial Septal Defects (ASD) and Patent Foramen Ovale (PFO): Congenital holes in the wall separating the heart's upper chambers.
• Cardiac Tumors: Benign intracardiac masses, such as atrial myxomas or fibroelastomas.
• Tricuspid Valve Disease: Severe tricuspid valve regurgitation requiring annuloplasty or repair, often concurrent with mitral procedures.

Preoperative preparation for robotic cardiac surgery involves detailed anatomical and vascular mapping. Patients undergo high-resolution contrast-enhanced CT angiography of the chest, abdomen, and pelvis to confirm that the femoral and iliac arteries are free of severe atherosclerosis or tortuosity, ensuring safe peripheral cannulation. Routine testing includes a transthoracic and transesophageal echocardiogram, cardiac catheterization (coronary angiogram), pulmonary function tests, and routine blood panels. Patients must stop specific blood-thinning medications (such as warfarin, clopidogrel, or direct oral anticoagulants) 3 to 7 days prior to surgery under medical supervision. Fasting begins at midnight prior to the scheduled procedure.

Complications of robotic cardiac surgery include potential general surgical risks and procedure-specific events. Minor side effects include port-site pain, intercostal neuralgia (numbness or tingling along the ribs), and localized groin bruising. Major complications, though rare, include stroke (1-2%), perioperative myocardial infarction (1%), groin vascular dissection or thrombosis from femoral cannulation (1-2%), and phrenic nerve injury leading to diaphragmatic dysfunction (1%). Unplanned intraoperative conversion to open median sternotomy occurs in approximately 1% to 3% of cases due to dense adhesions, anatomical complexity, or bleeding. Long-term risks include recurrent valve leakage requiring secondary intervention.

The clinical journey begins with a comprehensive preoperative workup, including computed tomography (CT) angiography to evaluate vascular access in the pelvis and legs. On the day of surgery, general anesthesia is administered, and the patient is placed on cardiopulmonary bypass via femoral cannulation (groin tube placement). The surgeon controls high-precision robotic arms from a console adjacent to the operating table, executing the repair or bypass. After procedure completion, the heart is restarted, robotic instruments are removed, and the patient is transferred to the cardiac intensive care unit (ICU). Most patients are extubated within hours, step down to a standard ward by day two, and achieve full recovery within three to four weeks.